A new personalized treatment after melanoma surgery: what it means for you

-

Merck and Moderna have announced that a personalized mRNA cancer vaccine given together with the immunotherapy drug pembrolizumab (brand name Keytruda) helped people with high‑risk melanoma stay cancer‑free longer after their tumor was removed by surgery. 

This is the first large (Phase 3) trial to show that an individualized, mRNA‑based cancer therapy can improve outcomes compared with pembrolizumab alone in this setting. 

It’s also a rare example of two major companies working closely together: Moderna, known for its mRNA vaccine technology, and Merck, a global pharmaceutical leader that makes pembrolizumab (Keytruda). Their partnership combines Moderna’s personalized vaccine platform with Merck’s proven immunotherapy, something experts say could open the door to similar combinations for other cancers. 

Who was in the study?

  • 1,137 adults with stage IIB–IV melanoma (a serious form of skin cancer) whose tumors had been completely removed by surgery and who had not yet received whole‑body cancer treatment. 

  • Patients were randomly assigned to one of two groups:

    • Pembrolizumab (Keytruda) alone (the current standard after surgery), or
    • Pembrolizumab (Keytruda) + the personalized mRNA vaccine (intismeran). 

What did they find?

At a planned interim check, the combination met its main goals:

No new safety problems were seen compared with what was already known for pembrolizumab and the vaccine platform; earlier studies reported mostly mild to moderate side effects such as fatigue, injection‑site pain, and chills. 

The companies plan to present the full numbers (how big the benefit was, exact side‑effect rates) at a medical meeting and to seek regulatory approval in the coming months. 

Why combine a vaccine with pembrolizumab (Keytruda)? (the logic in plain language)

Think of the immune system as an army that can recognize and destroy cancer cells—but cancer often hides or puts the immune system “to sleep.”

1) What pembrolizumab (Keytruda) does

  • Pembrolizumab (Keytruda) is an immunotherapy that releases the brakes on immune cells (T‑cells) so they can attack cancer more effectively. 
  • It works well for many people, but not everyone stays cancer‑free after surgery, because the immune system may still not “see” the cancer clearly enough.

2) What the personalized mRNA vaccine does

  • Each patient’s tumor is analyzed to find its unique set of mutations (its “fingerprint”). 
  • A custom mRNA vaccine is then made that encodes up to 34 neoantigens—small pieces of those mutated proteins that are specific to that person’s cancer. 
  • When injected, the vaccine teaches the immune system to recognize those neoantigens, helping T‑cells find and kill any remaining cancer cells that carry them. 

3) Why the combination is powerful

  • Pembrolizumab (Keytruda) removes the immune system’s brakes.
  • The vaccine gives the immune system a clear, personalized target to aim at.

Together, they aim to create a stronger, more focused anti‑cancer response than either approach alone—especially important after surgery when only tiny amounts of cancer may be left behind. 

Why this two‑company partnership matters

  • Moderna brings the mRNA vaccine technology that can be quickly customized to each patient’s tumor. Merck brings pembrolizumab (Keytruda), one of the most widely used cancer immunotherapies, plus extensive experience running large global trials and working with regulators. Experts say this success could encourage more collaborations between vaccine developers and drug companies to test similar combinations in lung, bladder, kidney, pancreatic, and other cancers. 

In other words, this isn’t just about one drug—it’s a proof of concept that personalized mRNA vaccines can work alongside existing immunotherapies, potentially changing how several solid tumors are treated. 

What this could mean for patients

If regulators approve this regimen, it could become a new standard after surgery for high‑risk melanoma, with the goal of:

  • Lowering the chance that melanoma returns, and
  • Reducing the risk that it spreads to other organs. 

Because the vaccine is made to order from each person’s tumor, it represents a shift toward truly personalized cancer treatment. 

When might this be available in real medical practice?

Based on the companies’ statements and typical timelines:

  • Full data presentation: The detailed results are expected to be shown at an upcoming major cancer meeting (often ASCO, ESMO, or SITC), which will give doctors the exact benefit and safety numbers. 
  • Regulatory review: After the full dataset is public, Merck and Moderna plan to file for approval with regulators (such as the U.S. FDA and European EMA). Given the strong Phase 3 results and unmet need, this could happen within months of the full presentation. 
  • Real‑world availability: If approvals go smoothly, the combination could start reaching clinics in the next 1–2 years, first in specialized cancer centers that can handle the personalized vaccine manufacturing and logistics. 

Exact timing will depend on how quickly the full data are published, how regulators review the submission, and how fast manufacturing and distribution can be scaled for a “made‑to‑order” therapy. 

Mykola Iabluchanskyi together with Andriy Yabluchanskiy


Comments

Post a Comment

Popular posts from this blog

Menopause Is Not a Gumboil: Answering Clinical Misunderstandings in Light of Medscape

-
Image
Menopause is one of the major physiological stages in a woman’s life, as natural as childhood, adulthood and old age. It marks the end of reproductive function, but not the end of health, agency or dignity. Yet in contemporary medicine, menopause is often treated as a problem to be fixed rather than a normal biological transition to be understood. Recently, a Medscape article on the “hidden burdens” of menopause presented a detailed catalogue of new symptom clusters and proposed multiple interventions . It is a useful clinical document, but it raises a deeper question: are we still thinking about menopause itself as a physiological period in a woman’s life, or have we begun to treat the life stage as a disease? In this essay, we argue that menopause and postmenopause are physiological stages. Good clinical practice must start from this fact. Only on this basis can we distinguish genuine disease from the ordinary signs of a life stage, avoid misdiagnosis, and use hormone therapy and ...
Read more

Two Sides of Frailty: Vulnerability, Compensation, and a Consciousness-Centered Medicine of Aging

-
Image
Why This Book Must Be Written Modern science has learned to describe the aging body with extraordinary precision. It can measure inflammation, vascular stiffness, mitochondrial dysfunction, sarcopenia, osteoporosis, sleep disruption, cognitive slowing, frailty, disability, and mortality. It has identified mechanisms that increase vulnerability, created therapies that prevent suffering, restored function after illness, and extended human life. These achievements are indispensable. This book is not written against physiology, geroscience, geriatrics, frailty research, rehabilitation, neuroscience, or medicine. It is written because their common organization of thought remains incomplete. Contemporary aging science commonly places aging physiology at the center and consciousness at the periphery. It begins with the body: cells, tissues, organs, metabolism, inflammation, vessels, muscles, neural networks, biomarkers, disease burden, functional decline, and risk of death. Only later does it...
Read more

The Excellence of My Age

-
Image
  The Excellence of My Age I am seventy‑six and a half, retired for a long time, and I feel that I have reached a new kind of excellence in my life. Every day, age sends me its gifts in the form of changes in my body and mind. I do not meet them with fear; I meet them with interest. I watch what happens in my physical and mental dimensions and I study these changes as I would study any complex system. In earlier years, when something related to my health appeared, it demanded strong cognitive effort. I had to think hard: What is happening? What does it mean? Is it dangerous? Today the situation is much better. I now understand why these things happen. I carry in my mind many answers, built from decades in medicine and from observing my own aging. Because I know the causes, aging is not only a series of problems; it has become a field of personal research. You may feel, reading these words, that I am offending you by speaking too directly about decline, loss, or the realities of a...
Read more